Fractyl Health (GUTS) Profit After Tax (2023 - 2026)
Fractyl Health's (GUTS) quarterly Profit After Tax came in at $9.2 million in Q1 2026, up 138.84% YoY from $3.9 million in Q1 2025, and up 121.08% on a QoQ basis from -$43.7 million in Q4 2025.
Fractyl Health (GUTS) Profit After Tax (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Profit After Tax data on file, last reported at $9.2 million in Q1 2026.
- Quarterly Profit After Tax rose 138.84% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.0 million (down 21.2% YoY) and the FY2025 annual result came in at -$141.0 million, down 105.19% from the prior year.
- Profit After Tax improved to $9.2 million in Q1 2026, from -$43.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $9.2 million in Q1 2026 to a low of -$45.6 million in Q3 2025.
- A 4-year average of -$21.3 million and a median of -$23.2 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax sank 614.48% — and 2026, when it jumped 138.84%.
- Tracing GUTS's Profit After Tax over 4 years: stood at -$19.2 million in 2023, then sank by 30.19% to -$25.0 million in 2024, then plunged by 75.12% to -$43.7 million in 2025, then surged by 121.08% to $9.2 million in 2026.
- The last three Profit After Tax figures came in at $9.2 million (Q1 2026), -$43.7 million (Q4 2025), and -$45.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -25.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.54 Mn |
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | -43.73 Mn |
| Sep 30, 2025 | -45.60 Mn |
| Jun 30, 2025 | -27.89 Mn |
| Mar 31, 2025 | -23.74 Mn |
| Dec 31, 2024 | -24.97 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | -17.23 Mn |
| Mar 31, 2024 | -3.32 Mn |
| Dec 31, 2023 | -19.18 Mn |
| Sep 30, 2023 | -15.75 Mn |
| Jun 30, 2023 | -30.23 Mn |
| Mar 31, 2023 | -11.93 Mn |